Company Filing History:
Years Active: 2014-2016
Title: The Innovations of Inventor Daniel Zurr
Introduction
Daniel Zurr, an inventive researcher based in Herzlia Pituach, Israel, has made significant contributions to the field of biopharmaceuticals. With three patents to his name, Zurr's work is focused on innovative treatments for various medical conditions, especially in the realm of gene therapy.
Latest Patents
Zurr's latest patent revolves around oligoribonucleotides and their therapeutic uses for treating conditions such as alopecia and acute renal failure. This invention describes a double-stranded compound, preferably an oligoribonucleotide, which functions by down-regulating the expression of the human p53 gene. Additionally, the patent outlines a pharmaceutical composition that includes this compound, as well as a vector capable of expressing the oligoribonucleotide, and a pharmaceutically acceptable carrier. The application also provides methods for treating patients suffering from alopecia or acute renal failure, particularly in cases induced by chemotherapy or radiotherapy in patients with cancer, including breast cancer.
Career Highlights
Daniel Zurr is currently associated with Quark Pharmaceuticals, Inc., where he continues to advance his research and innovations. His deep understanding of genetic therapies has positioned him as a key figure within the biopharmaceutical community.
Collaborations
Throughout his career, Zurr has collaborated with several esteemed professionals in the industry, including notable colleagues Elena Feinstein and Shai Ehrlich. These collaborations contribute to a collaborative approach that fosters innovation and the development of cutting-edge therapeutic solutions.
Conclusion
Daniel Zurr's dedication to developing novel biopharmaceutical solutions illustrates the profound impact that innovative thinking can have on medical science. His patented inventions are not only a testament to his ingenuity but also highlight the potential for advancements in treatments for patients battling serious health conditions. His continued work at Quark Pharmaceuticals, Inc. promises further contributions to the healthcare landscape.